849 related articles for article (PubMed ID: 23968703)
1. Clinical implications of very low on-treatment platelet reactivity in patients treated with thienopyridine: the POBA study (predictor of bleedings with antiplatelet drugs).
Cuisset T; Grosdidier C; Loundou AD; Quilici J; Loosveld M; Camoin L; Pankert M; Beguin S; Lambert M; Morange PE; Bonnet JL; Alessi MC
JACC Cardiovasc Interv; 2013 Aug; 6(8):854-63. PubMed ID: 23968703
[TBL] [Abstract][Full Text] [Related]
2. Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel.
Bonello L; Mancini J; Pansieri M; Maillard L; Rossi P; Collet F; Jouve B; Wittenberg O; Laine M; Michelet P; Bessereau J; Lemesle G; Dignat-George F; Paganelli F; Camoin-Jau L
J Thromb Haemost; 2012 Oct; 10(10):1999-2005. PubMed ID: 22863374
[TBL] [Abstract][Full Text] [Related]
3. Platelet reactivity in diabetic patients undergoing coronary stenting for acute coronary syndrome treated with clopidogrel loading dose followed by prasugrel maintenance therapy.
Cuisset T; Gaborit B; Dubois N; Quilici J; Loosveld M; Beguin S; Loundou AD; Moro PJ; Morange PE; Alessi MC; Dutour A; Bonnet JL
Int J Cardiol; 2013 Sep; 168(1):523-8. PubMed ID: 23084816
[TBL] [Abstract][Full Text] [Related]
4. Optimizing P2Y12 receptor inhibition in patients with acute coronary syndrome on the basis of platelet function testing: impact of prasugrel and high-dose clopidogrel.
Aradi D; Tornyos A; Pintér T; Vorobcsuk A; Kónyi A; Faluközy J; Veress G; Magyari B; Horváth IG; Komócsi A
J Am Coll Cardiol; 2014 Mar; 63(11):1061-70. PubMed ID: 24486281
[TBL] [Abstract][Full Text] [Related]
5. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unselected patients treated by percutaneous coronary angioplasty: a prospective registry.
El Ghannudi S; Ohlmann P; Meyer N; Wiesel ML; Radulescu B; Chauvin M; Bareiss P; Gachet C; Morel O
JACC Cardiovasc Interv; 2010 Jun; 3(6):648-56. PubMed ID: 20630458
[TBL] [Abstract][Full Text] [Related]
6. Nuisance and alarming bleeding do not correlate with on-treatment platelet reactivity.
Gaglia MA; Torguson R; Pokharel S; Pakala R; Xue Z; Suddath WO; Kent KM; Satler LF; Pichard AD; Waksman R
Cardiovasc Revasc Med; 2013; 14(2):76-80. PubMed ID: 23375617
[TBL] [Abstract][Full Text] [Related]
7. Multiple electrode aggregometry and vasodilator stimulated phosphoprotein-phosphorylation assay in clinical routine for prediction of postprocedural major adverse cardiovascular events.
Freynhofer MK; Brozovic I; Bruno V; Farhan S; Vogel B; Jakl G; Willheim M; Hübl W; Wojta J; Huber K
Thromb Haemost; 2011 Aug; 106(2):230-9. PubMed ID: 21614416
[TBL] [Abstract][Full Text] [Related]
8. Predictive values of post-treatment adenosine diphosphate-induced aggregation and vasodilator-stimulated phosphoprotein index for stent thrombosis after acute coronary syndrome in clopidogrel-treated patients.
Cuisset T; Frere C; Quilici J; Gaborit B; Castelli C; Poyet R; Bali L; Morange PE; Alessi MC; Bonnet JL
Am J Cardiol; 2009 Oct; 104(8):1078-82. PubMed ID: 19801028
[TBL] [Abstract][Full Text] [Related]
9. Switching acute coronary syndrome patients from prasugrel to clopidogrel.
Kerneis M; Silvain J; Abtan J; Cayla G; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Martin R; Collet JP; Montalescot G
JACC Cardiovasc Interv; 2013 Feb; 6(2):158-65. PubMed ID: 23428007
[TBL] [Abstract][Full Text] [Related]
10. Double-blind, randomized, prospective comparison of loading doses of 600 mg clopidogrel versus 60 mg prasugrel in patients with acute ST-segment elevation myocardial infarction scheduled for primary percutaneous intervention: the ETAMI trial (early thienopyridine treatment to improve primary PCI in patients with acute myocardial infarction).
Zeymer U; Mochmann HC; Mark B; Arntz HR; Thiele H; Diller F; Montalescot G; Zahn R
JACC Cardiovasc Interv; 2015 Jan; 8(1 Pt B):147-154. PubMed ID: 25616919
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of platelet response to clopidogrel by point-of-care testing to predict bleeding outcomes in patients undergoing percutaneous coronary intervention (from the Antiplatelet Therapy for Reduction of Myocardial Damage During Angioplasty-Bleeding Study).
Patti G; Pasceri V; Vizzi V; Ricottini E; Di Sciascio G
Am J Cardiol; 2011 Apr; 107(7):995-1000. PubMed ID: 21256470
[TBL] [Abstract][Full Text] [Related]
12. Identification of poor response to P2Y12 inhibitors in ACS patients with a new ELISA-based vasodilator-associated stimulated phosphoprotein (VASP) phosphorylation assay.
Abtan J; Silvain J; Kerneis M; O'Connor SA; Barthélémy O; Vignalou JB; Beygui F; Brugier D; Collet JP; Montalescot G
Thromb Haemost; 2013 Nov; 110(5):1055-64. PubMed ID: 23925438
[TBL] [Abstract][Full Text] [Related]
13. Platelet reactivity inhibition following ticagrelor loading dose in patients undergoing percutaneous coronary intervention for acute coronary syndrome.
Laine M; Panagides V; Frère C; Cuisset T; Gouarne C; Jouve B; Thuny F; Paganelli F; Alessi MC; Mancini J; Bonello L
J Thromb Haemost; 2019 Dec; 17(12):2188-2195. PubMed ID: 31351022
[TBL] [Abstract][Full Text] [Related]
14. Impact of obesity and the metabolic syndrome on response to clopidogrel or prasugrel and bleeding risk in patients treated after coronary stenting.
Pankert M; Quilici J; Loundou AD; Verdier V; Lambert M; Deharo P; Bonnet G; Gaborit B; Morange PE; Valéro R; Dutour A; Bonnet JL; Alessi MC; Cuisset T
Am J Cardiol; 2014 Jan; 113(1):54-9. PubMed ID: 24182762
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic effects of standard dose prasugrel versus high dose clopidogrel in non-diabetic obese patients with coronary artery disease.
Darlington A; Tello-Montoliu A; Rollini F; Ueno M; Ferreiro JL; Patel R; Desai B; Guzman LA; Bass TA; Angiolillo DJ
Thromb Haemost; 2014 Feb; 111(2):258-65. PubMed ID: 24154863
[TBL] [Abstract][Full Text] [Related]
16. Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial.
Michelson AD; Frelinger AL; Braunwald E; Downey WE; Angiolillo DJ; Xenopoulos NP; Jakubowski JA; Li Y; Murphy SA; Qin J; McCabe CH; Antman EM; Wiviott SD;
Eur Heart J; 2009 Jul; 30(14):1753-63. PubMed ID: 19435740
[TBL] [Abstract][Full Text] [Related]
17. A comparative cohort study on personalised antiplatelet therapy in PCI-treated patients with high on-clopidogrel platelet reactivity. Results of the ISAR-HPR registry.
Mayer K; Schulz S; Bernlochner I; Morath T; Braun S; Hausleiter J; Massberg S; Schunkert H; Laugwitz KL; Kastrati A; Sibbing D
Thromb Haemost; 2014 Aug; 112(2):342-51. PubMed ID: 24718389
[TBL] [Abstract][Full Text] [Related]
18. Relationship between pharmacokinetics and pharmacodynamics of clopidogrel in patients undergoing percutaneous coronary intervention: comparison between vasodilator-stimulated phosphoprotein phosphorylation assay and multiple electrode aggregometry.
Danese E; Fava C; Beltrame F; Tavella D; Calabria S; Benati M; Gelati M; Gottardo R; Tagliaro F; Guidi GC; Cattaneo M; Minuz P
J Thromb Haemost; 2016 Feb; 14(2):282-93. PubMed ID: 26576037
[TBL] [Abstract][Full Text] [Related]
19. Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel.
Roe MT; Goodman SG; Ohman EM; Stevens SR; Hochman JS; Gottlieb S; Martinez F; Dalby AJ; Boden WE; White HD; Prabhakaran D; Winters KJ; Aylward PE; Bassand JP; McGuire DK; Ardissino D; Fox KA; Armstrong PW
Circulation; 2013 Aug; 128(8):823-33. PubMed ID: 23852610
[TBL] [Abstract][Full Text] [Related]
20. Comparison between initial and chronic response to clopidogrel therapy after coronary stenting for acute coronary syndrome and influence on clinical outcomes.
Cuisset T; Quilici J; Loosveld M; Gaborit B; Grosdidier C; Fourcade L; Gil JM; Moro PJ; Morange PE; Bonnet JL; Alessi MC
Am Heart J; 2012 Sep; 164(3):327-33. PubMed ID: 22980298
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
